NCT00696124 - Safety Study of Gene Therapy in Treating Critical Leg Ischemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 3, 2007

Primary Completion Date

October 19, 2009

Study Completion Date

December 11, 2023

Conditions

Critical Limb Ischemia

Interventions

BIOLOGICAL

VM202 2 mg

2 mg intramuscular injection with the first half of the total dose given on Day 1 and the second half on Day 15

BIOLOGICAL

VM202 4 mg

4 mg intramuscular injection, with half of the total dose given on Day 1 and the second half given on Day 15

BIOLOGICAL

VM202 8 mg

8 mg intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.

BIOLOGICAL

VM202 16 mg

16 mg dose intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.

Trial Locations (1)

Minneapolis Heart Institute Foundation/ Abbott Northwestern Hospital, Minneapolis

All Listed Sponsors

lead

Helixmith Co., Ltd.

INDUSTRY